Parsaclisib

DB14867InvestigationalSmall molecule

Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

Chemical structure of Parsaclisib
Mechanism
Curator reviewed
Formula / weight
C20H22ClFN6O2 · 432.88 g/mol (avg)
Also known as
INCB050465
Code names
INCB-50465 · WHO 10589

Resolves to

Compound
UNIIOS7097575KCAS1426698-88-5
Clinical / RWD
ATCL01EM05
Structure
InChIKeyZQPDJCIXJHUERQ-QWRGUYRKSA-NSMILESCCOC1=C(C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1)[C@H](C)N1N=C(C)C2=C1N=CN=C2N
Targets
O00329PIK3CD

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
34Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 4 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Parsaclisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In